StocksMedium•3 November 2026•
1 min read
Vertex Pharmaceuticals Misses Q3 Profit Estimates, Raises 2026 Sales Outlook
Key Facts
1Vertex Pharmaceuticals reported quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92.
2Revenue reached $3.44 billion, beating estimates of $3.42 billion, driven by cystic fibrosis drug sales and growth in Casgevy and Journavx.
3The company raised its sales outlook for 2026 following the strong revenue performance in the third quarter.
Vertex Pharmaceuticals reported quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92. Zacks reported that revenue reached $3.44 billion, beating estimates of $3.42 billion. The performance was driven by strong sales of cystic fibrosis treatments and growth in new products including Casgevy and Journavx.
The company raised its sales outlook for the full year 2026 following the strong revenue performance in the third quarter. This improved guidance is supported by sustained demand for core cystic fibrosis therapies and the successful rollout of new treatments.